Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Maruzzo

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
Journal for Immunotherapy of Cancer|May 26, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinomaJulius Strauss, Jean-Laurent Deville, Mario Sznol, et al.
Clinical Genitourinary Cancer|December 11, 2024
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or EnzalutamideOrazio Caffo, Umberto Basso, Carlo Cattrini, et al.
Clinical Genitourinary Cancer|June 29, 2022
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or CabozantinibRoberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, et al.
In Vivo (Athens, Greece)|October 30, 2025
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER StudyElisabetta Gambale, Roberta Giorgione, Umberto Basso, et al.
European Urology Open Science|October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Future Oncology (London, England)|April 28, 2025
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPCAntonello Veccia, Umberto Basso, Carlo Cattrini, et al.
International Journal of Molecular Sciences|January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
The New England Journal of Medicine|May 10, 2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Laurence Albiges, et al.
Cancers|May 28, 2022
Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, ItalyAntonella Brunello, Antonella Galiano, Stefania Schiavon, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|May 26, 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinomaJulius Strauss, Jean-Laurent Deville, Mario Sznol, et al.
Clinical Genitourinary Cancer|December 11, 2024
Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or EnzalutamideOrazio Caffo, Umberto Basso, Carlo Cattrini, et al.
Clinical Genitourinary Cancer|June 29, 2022
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or CabozantinibRoberto Iacovelli, Chiara Ciccarese, Marco Maruzzo, et al.
In Vivo (Athens, Greece)|October 30, 2025
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER StudyElisabetta Gambale, Roberta Giorgione, Umberto Basso, et al.
European Urology Open Science|October 27, 2025
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)Marco Stellato, Pierangela Sepe, Enrico Bronte, et al.
Future Oncology (London, England)|April 28, 2025
Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPCAntonello Veccia, Umberto Basso, Carlo Cattrini, et al.
International Journal of Molecular Sciences|January 21, 2023
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Future Oncology (London, England)|May 19, 2018
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programSergio Bracarda, Luca Galli, Marco Maruzzo, et al.
The New England Journal of Medicine|May 10, 2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Laurence Albiges, et al.
Cancers|May 28, 2022
Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, ItalyAntonella Brunello, Antonella Galiano, Stefania Schiavon, et al.
Pageof 15